Pedigree assessment tool breast cancer

Comparisons were made between models in ability to discriminate patients appropriate for genetic evaluation based on accuracy in predicting a positive test result. Records evaluated represent families. BRCA testing revealed mutation-positive and mutation-negative families. This is a preview of subscription content, access via your institution.

Rent this article via DeepDyve. The genetic attributable risk of breast and ovarian cancer. Wooster R, Weber BL. Breast and ovarian cancer. N Engl J Med. Article Google Scholar. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.

Am J Hum Genet. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families.

Changes in psychological distress after cancer genetic counseling: a comparison of affected and unaffected women. Br J Cancer. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.

Article PubMed Google Scholar. Breast cancer risk screening tool. Accessed 5 Feb Quantitative breast cancer risk assessment. In: Vogel VG, editor. Management of patients at high risk for breast cancer. Blackwell, Malden; Google Scholar.

Application of breast cancer risk prediction models in clinical practice. J Clin Oncol. Myriad BRCA risk calculator and mutation prevalence tables. Myriad BRCA risk calculator. Evaluating the yield of medical tests. The American Society of Clinical Oncology.

Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility. Did any man in your family have breast cancer? Did any woman in your family have breast and ovarian cancer? Did any woman in your family have breast cancer before age of 50 years? Ann Intern Med. PMID Clin Genet. J Med Genet. PMC CS1 maint: Explicit use of et al.

Genet Med. Read the Issue. Sign Up Now. Feb 15, Issue. Am Fam Physician. Other relevant USPSTF recommendations The USPSTF recommends that clinicians offer to prescribe risk-reducing medications such as tamoxifen, raloxifene, or aromatase inhibitors to women at increased risk for breast cancer and at low risk for adverse medication effects. TABLE 1. TABLE 2. TABLE 3. If yes, complete checklist. TABLE 4. TABLE 5. Questions 1 Did any of your first-degree relatives have breast or ovarian cancer?

TABLE 6. TABLE 7. Read the full article. Get immediate access, anytime, anywhere. Choose a single article, issue, or full-access subscription. Earn up to 6 CME credits per issue. Purchase Access: See My Options close. Best Value!

To see the full article, log in or purchase access. References show all references 1. More in Pubmed Citation Related Articles.

Email Alerts Don't miss a single issue. Sign up for the free AFP email table of contents. Navigate this Article. Assess with an appropriate brief familial risk assessment tool. Risk assessment. Genetic counseling. Genetic testing.

Treatment and interventions. Breast cancer relatives. Male relative add to above. Breast cancer characteristics. Ovarian cancer relatives. Ovarian cancer onset, y. Prostate cancer onset. Colon cancer onset. Family total:. Female breast cancer, y. Male breast cancer, y. Total individual genes. Male breast cancer at any age in any relative. Ovarian cancer at any age. Male breast cancer at any age. Ashkenazi Jewish heritage.